At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Innovative Medicines Initiative
  • Initiator Type: Government
  • Rare disease
  • Disease focus:
  • Location: Europe


The PreDiCT-TB (Model-based preclinical development of anti-tuberculosis drug combinations) consortium is a 60-month effort from the Innovative Medicines Initiative (IMI) to accelerate the search for new, more effective combinations of treatments to tackle tuberculosis (TB). The consortium’s focus is to address preclinical research barriers to the discovery and development of new TB drug combinations.


PreDiCT-TB aims to overcome the challenges in TB drug development by creating tools to accelerate pharmacokinetic/pharmacodynamic (PK-PD) analysis that are connected to clinical outcomes. By addressing the gaps in preclinical information, the consortium aims to provide a framework and tools to facilitate the transition of the best combinations of drugs to late phase development.

The aims of the consortium are as follows:

Consortium History

2012: Project launched
July 2012: PreDiCT-TB and Critical Path to TB Drug Regimens (CPTR) announced joint meeting on TB
August 2012: European & Developing Countries Clinical Trials Partnership awarded grant to Stephen Gellespie and other members of the PacACEA and PreDiCT-TB consortia
September 2012: Bedaquiline, an investigational new drug developed by Janssen and scheduled to be included in the second round of PreDiCT-TB, granted accelerated approval by the U.S. Food and Drug Administration (FDA)
March 2013: PreDiCT-TB signed Memorandum of Understanding with Critical Path Institute’s (C-Path’s) CPTR projects to coordinate work
February 2014: Louise Cooper appointed new project manager

Structure & Governance

The governance of the PreDiCT-TB consortium follows the framework for all consortia supported by the IMI. In addition to a Steering Committee, the consortium relies on several working groups and boards, such as an Ethics Advisory Board.


This project is funded by the IMI, a public-private partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), resources of which are composed of financial contribution from the EU Seventh Framework Programme and EFPIA companies’ in kind contribution. Large pharmaceutical companies participating in IMI projects do not receive IMI funding. IMI contributed €14.8 million, EFPIA contributed €9.3 million in kind, and other sources contributed €4.5 million, for a total cost of €28.6 million.

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing The IMI IP policy can be accessed at

Data Sharing

According to IMI’s IP policy, the participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The project agreement shall include a description of the material, which must be disseminated in accordance with the IP policy and referenced in the grant agreement. If the participants do not disseminate within such time periods without good reason, then the Executive Office has the right to disseminate such results in a manner consistent with the grant agreement.


In 2013, PreDiCT-TB and C-Path’s CPTR project signed a Memorandum of Understanding to coordinate their work in developing new and effective treatment regimens for TB.

Points of Contact

Justin Green
phone: +44 20 8990 2092

Geraint Davies
University of Liverpool
phone: +44 151 428 0422

Sponsors & Partners

École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands

GlaxoSmithKline Investigación y Desarrollo SL, Tres Cantos, Spain

Health Protection Agency, London, UK

Institut Pasteur, Paris, France

Janssen Infectious Diseases – Diagnostics BVBA, Beerse, Belgium

Liverpool School of Tropical Medicine, Liverpool, UK

Max Planck Gesellschaft zur Förderung der Wissenschaften E.V., Munich, Germany

Microsens Medtech Ltd., London, UK

Sanofi-Aventis Research & Development, Chilly Mazarin, France

St George’s University of London, London, UK

Universidad Carlos III de Madrid, Madrid, Spain

University College London, London, UK

University of Leicester, Leicester, UK

University of Liverpool, Liverpool, UK

University of St. Andrews, St. Andrews, UK

Uppsala universitet, Uppsala, Sweden

Vrije Universiteit Medisch Centrum, Amsterdam, the Netherlands

ZF-Screens BV, Leiden, the Netherlands

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.